272 related articles for article (PubMed ID: 21999934)
1. Hypoxia, stem cells and bone tumor.
Zeng W; Wan R; Zheng Y; Singh SR; Wei Y
Cancer Lett; 2011 Dec; 313(2):129-36. PubMed ID: 21999934
[TBL] [Abstract][Full Text] [Related]
2. Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors.
Machado I; Navarro S; Giner F; Alberghini M; Bertoni F; Llombart-Bosch A
Virchows Arch; 2010 Jul; 457(1):87-9. PubMed ID: 20552365
[No Abstract] [Full Text] [Related]
3. Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor.
Knowles HJ; Schaefer KL; Dirksen U; Athanasou NA
BMC Cancer; 2010 Jul; 10():372. PubMed ID: 20637078
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy.
Xiang L; Semenza GL
Adv Cancer Res; 2019; 141():175-212. PubMed ID: 30691683
[TBL] [Abstract][Full Text] [Related]
5. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
6. Experimental therapies and clinical trials in bone sarcoma.
Chugh R
J Natl Compr Canc Netw; 2010 Jun; 8(6):715-25. PubMed ID: 20581301
[TBL] [Abstract][Full Text] [Related]
7. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
8. DEC2 expression is positively correlated with HIF-1 activation and the invasiveness of human osteosarcomas.
Hu T; He N; Yang Y; Yin C; Sang N; Yang Q
J Exp Clin Cancer Res; 2015 Feb; 34(1):22. PubMed ID: 25884381
[TBL] [Abstract][Full Text] [Related]
9. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.
Brooks DL; Schwab LP; Krutilina R; Parke DN; Sethuraman A; Hoogewijs D; Schörg A; Gotwald L; Fan M; Wenger RH; Seagroves TN
Mol Cancer; 2016 Mar; 15():26. PubMed ID: 27001172
[TBL] [Abstract][Full Text] [Related]
10. Pelvic bone sarcomas: controversies and treatment options.
Morris CD
J Natl Compr Canc Netw; 2010 Jun; 8(6):731-7. PubMed ID: 20581302
[TBL] [Abstract][Full Text] [Related]
11. Exosomes in Bone Sarcomas: Key Players in Metastasis.
Chicón-Bosch M; Tirado OM
Cells; 2020 Jan; 9(1):. PubMed ID: 31963599
[TBL] [Abstract][Full Text] [Related]
12. Kinome-wide functional genomics screen reveals a novel mechanism of TNFα-induced nuclear accumulation of the HIF-1α transcription factor in cancer cells.
Schoolmeesters A; Brown DD; Fedorov Y
PLoS One; 2012; 7(2):e31270. PubMed ID: 22355351
[TBL] [Abstract][Full Text] [Related]
13. Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.
Garofalo C; Capristo M; Manara MC; Mancarella C; Landuzzi L; Belfiore A; Lollini PL; Picci P; Scotlandi K
PLoS One; 2013; 8(12):e83832. PubMed ID: 24391834
[TBL] [Abstract][Full Text] [Related]
14. Recovery of stromal stem cells in bone sarcoma patients after chemotherapy: implication for cell-based therapy in bone defect reconstruction.
Beccheroni A; Lucarelli E; Donati D; Sangiorgi L; Capponcelli S; Gorini M; Zambon Bertoja A; Giardino R; Mercuri M; Ferrari S; Bacci G; Picci P
Oncol Rep; 2003; 10(4):891-6. PubMed ID: 12792741
[TBL] [Abstract][Full Text] [Related]
15. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours.
Boeuf S; Bovée JV; Lehner B; Hogendoorn PC; Richter W
Histopathology; 2010 Apr; 56(5):641-51. PubMed ID: 20459575
[TBL] [Abstract][Full Text] [Related]
16. Oncostatin M is a growth factor for Ewing sarcoma.
David E; Tirode F; Baud'huin M; Guihard P; Laud K; Delattre O; Heymann MF; Heymann D; Redini F; Blanchard F
Am J Pathol; 2012 Nov; 181(5):1782-95. PubMed ID: 22982441
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer.
Bendinelli P; Maroni P; Matteucci E; Luzzati A; Perrucchini G; Desiderio MA
Eur J Cancer; 2013 Jul; 49(11):2608-18. PubMed ID: 23566416
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of nm23 protein expression in malignant bone tumors.
Oda Y; Walter H; Radig K; Röse I; Neumann W; Roessner A
J Cancer Res Clin Oncol; 1995; 121(11):667-73. PubMed ID: 7593131
[TBL] [Abstract][Full Text] [Related]
19. Round cell tumors of bone: an update on recent molecular genetic advances.
Wei S; Siegal GP
Adv Anat Pathol; 2014 Sep; 21(5):359-72. PubMed ID: 25105937
[TBL] [Abstract][Full Text] [Related]
20. The role of hypoxia-inducible factors in breast cancer stem cell specification.
Karami Fath M; Garousi S; Mottahedi M; Ghasemzadeh N; Salmani K; Olfati F; Beit Saeed M; Sotoudeh S; Barati G
Pathol Res Pract; 2023 Mar; 243():154349. PubMed ID: 36791562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
